SPARC binding peptides and uses thereof
Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.
1. A composition for delivering a therapeutic or diagnostic agent to a disease site in a mammal comprising a therapeutically or diagnostically effective amount of the therapeutic or diagnostic agent coupled to a SPARC-binding-polyeptide (SBP) and a pharmaceutically acceptable carrier, wherein the SBP comprises any one or more of SEQ ID NOS: 1-112 or 117.
2. The composition of claim 1 , wherein the SBP comprises
two or more of SEQ ID NOs: SEQ ID NOs: 1-112.
3. The composition of claim 1 , wherein the SBP comprises two or more of SEQ ID NOs: 1-5.
4. The composition of claim 1 , wherein the SBPs are on two or more separate polypeptides and the SBPs are comprised of
a. any one of SEQ ID NOs: 1-5 or
b. two or more of SEQ ID NOs: 1-5.
5. The composition of claim 1 , wherein the SBP comprises SEQ ID NO: 1.
6. The composition of claim 1 , wherein the SBP comprises SEQ ID NO: 2.
7. The composition of claim 1 , wherein the SBP comprises SEQ ID NO: 117.
8. The composition of claim 1 , wherein there are two or more separate SBPs, wherein each individual SBP comprises any one of SEQ ID NOs: 1-112.
9. The composition of claim 1 , wherein there are two or more separate SBPs, wherein the individual SBPs are comprised of one or more of SEQ ID NOs: 1-5 or 117.
10. The composition of claim 1 , wherein the therapeutic or diagnostic agent is a therapeutic agent selected from the group consisting of platinum compounds, antifolates, antimetabolites, antimitotics, DNA damaging agents, proapoptotics, differentiation inducing agents, antiangiogenic agents, antibiotics, tyrosine kinase inhibitors, kinase inhibitors, biologically active agents, biological molecules, hormones, peptides, antibodies, antibodies fragments and combinations thereof.
11. The composition of claim 10 , wherein the therapeutic agent is an antibody fragment comprising a functional antibody Fc domain.
12. The composition of claim 10 , wherein the functional antibody Fc domain comprises SEQ ID NO: 118.
13. The composition of claim 10 , wherein the therapeutic agent is selected from the group consisting of radionuclides, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, docetaxel, paclitaxel, taxanes, 5-fluorouracil, anti-vascular endothelial growth factor compounds (“anti-VEGFs”), anti-epidermal growth factor receptor compounds (“anti-EGFRs”), genistein, tTF, TNF, Smar1 derived p44 peptide, interferon, TRAIL, Smac, VHL, procaspase, caspase, and IL-2, a non-Fc domain antibody fragment, and combinations thereof.
14. The composition of claim 1 , wherein the therapeutic or diagnostic agent is a diagnostic agent selected from the group consisting of radioactive agents, contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents.
15. The composition of claim 14 , further comprising an albumin binding peptide (ABP), wherein the ABP comprises a SEQ ID NO: 119 or SEQ ID NO: 120 or both SEQ ID NOS: 119 and 120.
16. The composition of claim 15 , wherein the SBP and the ABP are in the same polypeptide.
17. The composition of claim 15 , wherein the SBP and the ABP are in different polypeptides.
18. A method comprising administering the composition of claim 1 to a disease site in a mammal comprising a therapeutically or diagnostically effective amount of a pharmaceutical composition comprising the therapeutic or diagnostic agent coupled to a SPARC-binding-peptide and a pharmaceutically acceptable carrier, wherein the SBP comprises any one of SEQ ID NOS: 1-117.
19. The method of claim 18 , wherein the SBP comprises SEQ ID NO: 1.
20. The method of claim 18 , wherein the SBP comprises SEQ ID NO: 2.
21. The method of claim 18 , wherein the SBP comprises SEQ ID NO: 117.
22. The method claim 18 , wherein the therapeutic or diagnostic agent is a diagnostic agent selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents.
23. The method of claim 18 , wherein the disease site is a tumor.
24. The method of claim 18 , wherein the disease site is a site of abnormal conditions of cell proliferation, tissue remodeling, hyperplasia, exaggerated wound healing in any bodily tissue including soft tissue, connective tissue, bone, solid organs, blood vessel and the like.
25. The method of claim 18 , wherein the disease site is the site of diabetic or other retinopathy, inflammation, fibrosis, arthritis, restenosis in blood vessels or artificial blood vessel grafts or intravascular devices and the like, cataract and macular degeneration, osteoporosis, diseases of the hone, atherosclerosis and other diseases where calcification is frequently observed.
26. The method of claim 18 , wherein the mammal is a human patient.
27. The method of claim 18 , wherein the therapeutic or diagnostic agent is a therapeutic agent selected from the group consisting of platinum compounds, antifolates, antimetabolites, antimitotics, DNA damaging agents, proapoptotics, differentiation inducing agents, antiangiogenic agents, antibiotics, tyrosine kinase inhibitors, kinase inhibitors, biologically active agents, biological molecules, hormones, peptides, antibodies, antibodies fragments and combinations thereof.
28. The method of claim 27 , wherein the therapeutic agent is an antibody fragment comprising a functional antibody Fc domain.
29. The method of claim 28 , wherein the therapeutic agent is an antibody fragment which mediates one or more of complement activation, cell mediated cytotoxicity, inducing apoptosis, inducing cell death, and opsinization.
30. The method of claim 27 , wherein the antibody fragment comprises SEQ ID NO: 118.
31. The method of claim 27 , wherein the therapeutic agent is selected from the group consisting of radionuclides, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorobicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, docetaxel, paclitaxel, taxanes, 5-fluorouracil, anti-vascular endothelial growth factor compounds (“anti-VEGFs”), anti-epidermal growth factor receptor compounds (“anti-EGFRs”), genistein, tTF, TNF, Smar1 derived p44 peptide, interferon, TRAIL, Smac, procaspase, caspase, and IL-2, a non-Fc domain antibody fragment, and combinations thereof.
32. The method of claim 18 , wherein the composition further comprises an ABP comprising SEQ ID NOS: 119 or 120 or both SEQ ID NOS: 119 and 120.
33. The method of claim 23 , wherein the SBP and the ABP are in the same polypeptide.
34. The method of claim 23 , wherein the SBP and the ABP are in different polypeptides.